AgingResearch.NewsJoin free

Avelumab

Avelumab has been studied in 1 paper since 2020: none in people yet, 1 review. No study of it in people or animals has been published yet. The newest paper, May 7, 2020: “Timing of immune checkpoint inhibitors for metastatic patients over 75 years of age: the earlier the better”.

Intervention

1 paper studies itUpdated

See all 1 papers on avelumab

At a glance

48 trials, none about aging, 5 with no results posted.

Cells, worms or flies, mice and humans: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

About aging: the drug’s trials about aging. The total counts its trials for every use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

  • 48 trials, none about aging, 5 with no results posted
  • 14 of 48 trials sponsored by its developers

Who is developing avelumab?

3 companies: EMD Serono Research & Development Institute, G1 Therapeutics and Oncolytics Biotech.

Companies
  • EMD Serono Research & Development InstitutePhase 3first line non-small cell lung cancer
  • G1 TherapeuticsPhase 2urothelial carcinoma, bladder cancer
  • Oncolytics BiotechPhase 2breast cancer metastatic

Trial sponsors

Latest

Related